A citation-based method for searching scientific literature

Qian Chen, Yi-Yun Fu, Qiao-Ni Yue, Qian Wu, Yuan Tang, Wei-Ya Wang, Yong-Sheng Wang, Li-Li Jiang. Int J Clin Exp Pathol 2019
Times Cited: 12







List of co-cited articles
36 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
33

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
33

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
33

Emerging biomarkers for immune checkpoint inhibition in lung cancer.
George Cyriac, Leena Gandhi. Semin Cancer Biol 2018
56
25

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
25

PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
Enrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, Luigi Marchionni, Marcella Marconi, Marco Sommaggio, Matteo Brunelli, Guido Martignoni, George J Netto, Mohammad O Hoque,[...]. J Thorac Oncol 2018
98
25

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
815
25

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
25

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
M Dietel, N Savelov, R Salanova, P Micke, G Bigras, T Hida, J Antunez, B Guldhammer Skov, G Hutarew, L F Sua,[...]. Lung Cancer 2019
45
16

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Takaaki Tokito, Koichi Azuma, Akihiko Kawahara, Hidenobu Ishii, Kazuhiko Yamada, Norikazu Matsuo, Takashi Kinoshita, Naohisa Mizukami, Hirofumi Ono, Masayoshi Kage,[...]. Eur J Cancer 2016
131
16

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Joseph McLaughlin, Gang Han, Kurt A Schalper, Daniel Carvajal-Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy Herbst, Patricia LoRusso, David L Rimm. JAMA Oncol 2016
540
16


EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, Lecia V Sequist, Xiujun Fu, Christopher G Azzoli, Zofia Piotrowska, Tiffany G Huynh, Ling Zhao, Linnea Fulton, Katherine R Schultz,[...]. Clin Cancer Res 2016
688
16

The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara. Clin Lung Cancer 2018
43
16

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Muhammad Zaeem Noman, Giacomo Desantis, Bassam Janji, Meriem Hasmim, Saoussen Karray, Philippe Dessen, Vincenzo Bronte, Salem Chouaib. J Exp Med 2014
16

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
A D'Incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, C Tibaldi, G Minuti, J Salvini, E Coppi,[...]. Br J Cancer 2015
408
16

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Lingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Carl M Gay, Tina Cascone,[...]. J Thorac Oncol 2020
57
16

Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.
Julia R Naso, Gang Wang, Alexandra Pender, Selina K Wong, Jingyao Zhu, Cheryl Ho, Diana N Ionescu, Chen Zhou. Histopathology 2020
12
16

The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Matthew Evans, Brendan O'Sullivan, Frances Hughes, Tina Mullis, Matthew Smith, Nicola Trim, Philippe Taniere. Pathol Oncol Res 2020
37
16

Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Yuichi Saito, Sho Horiuchi, Hiroaki Morooka, Takayuki Ibi, Nobumasa Takahashi, Tomohiko Ikeya, Yoshihiko Shimizu, Eishin Hoshi. J Thorac Dis 2019
20
16

Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Sarah E Gradecki, Jacob S Grange, Edward B Stelow. Am J Surg Pathol 2018
21
16

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Jong-Mu Sun, Wei Zhou, Yoon-La Choi, So-Jung Choi, Se Eun Kim, Zhen Wang, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Wu, Russell Weiner,[...]. J Thorac Oncol 2016
115
16

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming Sound Tsao, Keith M Kerr, Mark Kockx, Mary-Beth Beasley, Alain C Borczuk, Johan Botling, Lukas Bubendorf, Lucian Chirieac, Gang Chen, Teh-Ying Chou,[...]. J Thorac Oncol 2018
399
16

Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Haipeng Xu, Xueyan Chen, Dong Lin, Jing Zhang, Chao Li, Dianbao Zhang, Xianfen Zhang. Onco Targets Ther 2019
6
33

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
16

The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Birgit Guldhammer Skov, Sara Bird Rørvig, Thomas Hartvig Lindkær Jensen, Torsten Skov. Mod Pathol 2020
20
16

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
16



Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Sehui Kim, Jaemoon Koh, Dohee Kwon, Bhumsuk Keam, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung. Eur J Cancer 2017
64
16

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
A J Schoenfeld, H Rizvi, C Bandlamudi, J L Sauter, W D Travis, N Rekhtman, A J Plodkowski, R Perez-Johnston, P Sawan, A Beras,[...]. Ann Oncol 2020
89
16

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Anne-Marie Boothman, Marietta Scott, Marianne Ratcliffe, Jessica Whiteley, Phillip A Dennis, Catherine Wadsworth, Alan Sharpe, Naiyer A Rizvi, Marina Chiara Garassino, Jill Walker. J Thorac Oncol 2019
24
16


PD-L1 Expression in Lung Cancer.
Hui Yu, Theresa A Boyle, Caicun Zhou, David L Rimm, Fred R Hirsch. J Thorac Oncol 2016
187
16

Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.
Peng Song, Shafei Wu, Li Zhang, Xuan Zeng, Jinghui Wang. Interdiscip Sci 2019
10
20



Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Shingo Inaguma, Zengfeng Wang, Jerzy Lasota, Maarit Sarlomo-Rikala, Peter A McCue, Hiroshi Ikeda, Markku Miettinen. Am J Surg Pathol 2016
61
8

Bronchial schwannomas: clinicopathologic analysis of 7 cases.
Yoon Yang Jung, Min Eui Hong, Joungho Han, Tae Sung Kim, Jhingook Kim, Young-Mog Shim, Hojoong Kim. Korean J Pathol 2013
12
8

Clinical Features and Surgical Treatment of Schwannoma Affecting the Base of the Tongue: A Systematic Review.
Jenna Lamendola Sitenga, Gregory Alan Aird, Austin Nguyen, Adam Vaudreuil, Christopher Huerter. Int Arch Otorhinolaryngol 2017
9
11


Intrapulmonary schwannoma.
Takashi Ohtsuka, Hiroaki Nomori, Tsuguo Naruke, Hideki Orikasa, Kazuto Yamazaki, Keiichi Suemasu. Jpn J Thorac Cardiovasc Surg 2005
14
8

The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning.
Emine Budak, Gürsel Çok, Ayşegül Akgün. Mol Imaging Radionucl Ther 2018
10
10

Schwannomas and their pathogenesis.
David A Hilton, Clemens Oliver Hanemann. Brain Pathol 2014
74
8


False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma-A Caution for Reporting Physicians.
Paul Boré, Renaud Descourt, Luc Ollivier, Pierre-Yves Le Roux, Ronan Abgral. Front Med (Lausanne) 2018
5
20

Schwannomas of the sinonasal tract and nasopharynx.
S L Hasegawa, T Mentzel, C D Fletcher. Mod Pathol 1997
59
8

Primary pulmonary tumours of neurogenic origin.
G Roviaro, M Montorsi, F Varoli, R Binda, A Cecchetto. Thorax 1983
41
8

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
George K Philips, Michael Atkins. Int Immunol 2015
223
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.